Please assess the completion status of the following clinical trial:

Trial Title: Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~The inclusion criteria for the study are broad reflecting the target population that would eventually receive an efficacious vaccine.~* Informed consent~* Age greater than or equal to 18 years~* Likely to be in the surrounding area of the vaccination center for at least one year.~EXCLUSION CRITERIA:~* Fever greater than or equal to 38.0 degrees Celsius~* History of EVD (self-report)~* Current pregnancy (a negative urine pregnancy test is required for women of child-bearing potential)~* Breast-feeding an infant~* Any condition which would limit the ability of the participant to meet the requirements of the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2 (Type: EXPERIMENTAL): ChAd3-EBO Z
- 3 (Type: EXPERIMENTAL): VSVG-ZEBOV
- 1 (Type: PLACEBO_COMPARATOR): Placebo (Saline)

Based on this trial design, predict the completion outcome and termination type (if applicable).